- Home
- GORO vs CABA Comparison
GORO vs CABA Comparison
Compare GORO & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GORO | CABA |
|---|---|---|
| Founded | 1998 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 497.8M | 462.9M |
| IPO Year | 2011 | 2019 |
Fundamental Metrics
Financial Performance| Metric | GORO | CABA |
|---|---|---|
| Price | $3.65 | $2.60 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $1.63 | ★ $14.50 |
| AVG Volume (30 Days) | 1.7M | ★ 5.3M |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 10.26 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $25.99 | N/A |
| Revenue Next Year | $5.78 | N/A |
| P/E Ratio | $70.67 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.62 | $1.90 |
| 52 Week High | $4.24 | $4.23 |
Technical Indicators
Market Signals| Indicator | GORO | CABA |
|---|---|---|
| Relative Strength Index (RSI) | 55.79 | 38.36 |
| Support Level | $0.88 | $2.02 |
| Resistance Level | $4.12 | $3.41 |
| Average True Range (ATR) | 0.29 | 0.26 |
| MACD | -0.08 | -0.08 |
| Stochastic Oscillator | 14.30 | 2.54 |
Price Performance
Historical ComparisonAbout GORO Gold Resource Corporation
Goldgroup Mining Inc is focused on the acquisition, exploration and development of stage gold-bearing mineral properties in the Americas. The Companies current gold production and exploration and development related activities are conducted in Mexico. It property portfolio include Cerro Prieto project in Sonora and Pinos Project.
About CABA Cabaletta Bio Inc.
Cabaletta Bio Inc is a late clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Its proprietary Cabaletta Approach to B cell Ablation (CABA) platform includes the CARTA approach, which uses chimeric antigen receptor T cells to eliminate B cells and potentially reset the immune system. The company develops cellular therapies including CAR T and CAAR T product candidates. Its candidate, rese-cel (resecabtagene autoleucel), a CD19-CAR T cell therapy, is being evaluated in Phase 1/2 trials for autoimmune diseases such as systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris.